Steven Ketchum

3.8k total citations · 1 hit paper
26 papers, 2.5k citations indexed

About

Steven Ketchum is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Molecular Biology. According to data from OpenAlex, Steven Ketchum has authored 26 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Surgery, 8 papers in Cardiology and Cardiovascular Medicine and 5 papers in Molecular Biology. Recurrent topics in Steven Ketchum's work include Lipoproteins and Cardiovascular Health (14 papers), Fatty Acid Research and Health (5 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (4 papers). Steven Ketchum is often cited by papers focused on Lipoproteins and Cardiovascular Health (14 papers), Fatty Acid Research and Health (5 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (4 papers). Steven Ketchum collaborates with scholars based in United States, France and Canada. Steven Ketchum's co-authors include Michael Miller, Christie M. Ballantyne, Ralph T. Doyle, Eliot A. Brinton, Philippe Gabríel Steg, Deepak L. Bhatt, Terry A. Jacobson, Lixia Jiao, Rebecca A. Juliano and Craig Granowitz and has published in prestigious journals such as New England Journal of Medicine, Nucleic Acids Research and Circulation.

In The Last Decade

Steven Ketchum

25 papers receiving 2.4k citations

Hit Papers

Cardiovascular Risk Reduction with Icosapent Ethyl for Hy... 2018 2026 2020 2023 2018 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
    2018 2.0k citations Deepak L. Bhatt, Philippe Gabríel Steg et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Steven Ketchum United States 10 1.2k 865 827 715 415 26 2.5k
Rebecca A. Juliano United States 18 1.5k 1.3× 1.1k 1.3× 1.2k 1.5× 898 1.3× 617 1.5× 40 3.1k
Craig Granowitz United States 18 1.6k 1.4× 1.3k 1.5× 992 1.2× 1.0k 1.4× 490 1.2× 55 3.2k
Francesca Pizzolo Italy 29 780 0.7× 937 1.1× 328 0.4× 444 0.6× 198 0.5× 83 2.5k
Jonathan L. Isaacsohn United States 22 1.5k 1.2× 725 0.8× 347 0.4× 582 0.8× 162 0.4× 50 2.4k
Michael Reardon Australia 17 775 0.6× 833 1.0× 552 0.7× 366 0.5× 283 0.7× 29 1.8k
Gabriele Bittolo Bon Italy 20 902 0.8× 870 1.0× 392 0.5× 451 0.6× 134 0.3× 43 2.3k
Esther Ooi Australia 28 1.1k 0.9× 937 1.1× 222 0.3× 539 0.8× 105 0.3× 81 2.2k
Shari Wang United States 21 1.3k 1.1× 1.0k 1.2× 380 0.5× 428 0.6× 92 0.2× 35 2.9k
J L Jenner United States 21 1.9k 1.6× 1.6k 1.9× 519 0.6× 736 1.0× 107 0.3× 25 3.1k
Marit S. Nenseter Norway 28 676 0.6× 303 0.4× 570 0.7× 223 0.3× 179 0.4× 57 2.0k

Countries citing papers authored by Steven Ketchum

Since Specialization
Citations

This map shows the geographic impact of Steven Ketchum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Ketchum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Ketchum more than expected).

Fields of papers citing papers by Steven Ketchum

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Ketchum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Ketchum. The network helps show where Steven Ketchum may publish in the future.

Co-authorship network of co-authors of Steven Ketchum

This figure shows the co-authorship network connecting the top 25 collaborators of Steven Ketchum. A scholar is included among the top collaborators of Steven Ketchum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven Ketchum. Steven Ketchum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bhatt, Deepak L., Robert P. Giugliano, Philippe Gabríel Steg, et al.. (2025). Benefit of icosapent ethyl across types and sizes of myocardial infarction in REDUCE-IT. European Journal of Preventive Cardiology.
2.
Szarek, Michael, Deepak L. Bhatt, Michael Miller, et al.. (2024). Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl. Journal of the American College of Cardiology. 83(16). 1529–1539. 9 indexed citations
3.
Previti, Mary Lou, Joshua Andrade, Raditya Utama, et al.. (2023). Gene recoding by synonymous mutations creates promiscuous intragenic transcription initiation in mycobacteria. mBio. 14(5). e0084123–e0084123. 2 indexed citations
4.
Szarek, Michael, Deepak L. Bhatt, Michael Miller, et al.. (2023). Eicosapentaenoic acid, arachidonic acid, and triglyceride levels mediate most of the benefit of icosapent ethyl in REDUCE-IT. European Heart Journal. 44(Supplement_2). 4 indexed citations
5.
Steg, Philippe Gabríel, Deepak L. Bhatt, Michael Miller, et al.. (2023). BENEFITS OF ICOSAPENT ETHYL IN PATIENTS WITH RECENT ACUTE CORONARY SYNDROME (ACS): REDUCE-IT ACS. Journal of the American College of Cardiology. 81(8). 1113–1113. 3 indexed citations
6.
Gaba, Prakriti, Deepak L. Bhatt, Philippe Gabríel Steg, et al.. (2022). Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction. Journal of the American College of Cardiology. 79(17). 1660–1671. 41 indexed citations
7.
Bhatt, Deepak L., Eliot A. Brinton, Michael Miller, et al.. (2022). ICOSAPENT ETHYL REDUCES CARDIOVASCULAR RISK SUBSTANTIALLY AND CONSISTENTLY REGARDLESS OF WAIST CIRCUMFERENCE. Journal of the American College of Cardiology. 79(9). 1556–1556. 2 indexed citations
8.
Wang, Xiaowen, Deepak L. Bhatt, Michael Miller, et al.. (2021). ICOSAPENT ETHYL REDUCES ISCHEMIC EVENTS IN PATIENTS WITH HIGH TRIGLYCERIDES AND LOW HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS: REDUCE-IT HIGH TG/LOW HDL-C ANALYSES. Journal of the American College of Cardiology. 77(18). 155–155. 2 indexed citations
9.
Gaba, Prakriti, Deepak L. Bhatt, Robert P. Giugliano, et al.. (2021). Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT. Journal of the American College of Cardiology. 78(15). 1525–1537. 23 indexed citations
10.
Olshansky, Brian, Deepak L. Bhatt, Michael Miller, et al.. (2021). Cardiovascular benefits outweigh risks in patients with atrial fibrillation in REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial). European Heart Journal. 42(Supplement_1). 3 indexed citations
11.
Bhatt, Deepak L., Philippe Gabríel Steg, Michael Miller, et al.. (2021). Abstract 10627: Benefits of Icosapent Ethyl in Patients with Prior Peripheral Artery Disease: REDUCE-IT PAD. Circulation. 144(Suppl_1). 6 indexed citations
12.
Peterson, Benjamin E., Deepak L. Bhatt, Philippe Gabríel Steg, et al.. (2020). TCT CONNECT-3 Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI. Journal of the American College of Cardiology. 76(17). B1–B2. 2 indexed citations
13.
Bhatt, Deepak L., Eliot A. Brinton, Michael Miller, et al.. (2020). 4-LB: Substantial Cardiovascular Benefit from Icosapent Ethyl in Patients with Diabetes: REDUCE-IT DIABETES. Diabetes. 69(Supplement_1). 9 indexed citations
14.
Bhatt, Deepak L., Philippe Gabríel Steg, Michael Miller, et al.. (2019). Effects of Icosapent Ethyl on Total Ischemic Events. Journal of the American College of Cardiology. 73(22). 2791–2802. 179 indexed citations
15.
Bhatt, Deepak L., Philippe Gabríel Steg, Michael Miller, et al.. (2018). Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New England Journal of Medicine. 380(1). 11–22. 2003 indexed citations breakdown →
16.
Zhou, Jia, Jiaqi Li, Rodolfo Bortolozo Serafim, et al.. (2018). Human CHD1 is required for early DNA-damage signaling and is uniquely regulated by its N terminus. Nucleic Acids Research. 46(8). 3891–3905. 28 indexed citations
17.
Ravandi, Farhad, Ellen K. Ritchie, Hamid Sayar, et al.. (2012). VALOR, an adaptive design, pivotal phase III trial of vosaroxin or placebo in combination with cytarabine in first relapsed or refractory acute myeloid leukemia.. Journal of Clinical Oncology. 30(15_suppl). TPS6637–TPS6637. 5 indexed citations
18.
Mehta, Cyrus R., Glenn Michelson, M.P. Salganik, et al.. (2011). Adaptive design of VALOR, a phase III trial of vosaroxin or placebo in combination with cytarabine for patients with first relapsed or refractory acute myeloid leukemia.. Journal of Clinical Oncology. 29(15_suppl). TPS201–TPS201. 5 indexed citations
19.
James, Iain F., et al.. (1990). Opioid receptor ligands in the neonatal rat spinal cord: binding and in vitro depression of the nociceptive responses. British Journal of Pharmacology. 99(3). 503–508. 9 indexed citations
20.
Haley, Jane E., Steven Ketchum, & Anthony H. Dickenson. (1990). Peripheral κ-opioid modulation of the formalin response: an electrophysiological study in the rat. European Journal of Pharmacology. 191(3). 437–446. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rebecca A. Juliano Breakdown of academic impact, for papers by Craig Granowitz Breakdown of academic impact, for papers by Francesca Pizzolo Breakdown of academic impact, for papers by Jonathan L. Isaacsohn Breakdown of academic impact, for papers by Michael Reardon Breakdown of academic impact, for papers by Gabriele Bittolo Bon Breakdown of academic impact, for papers by Esther Ooi Breakdown of academic impact, for papers by Shari Wang Breakdown of academic impact, for papers by J L Jenner Breakdown of academic impact, for papers by Marit S. Nenseter
Rankless by CCL
2026